Antiretroviral medication use among injection drug users: Two potential futures

AIDS

Volumn 14, Issue 9, 2000, Pages 1229-1235

  Wood, Evan ^a,b   Schechter, Martin T ^a,b   Tyndall, Mark W ^a,b   Montaner, Julio S G ^a,b,c   O'Shaughnessy, Michael V ^a,b   Hogg, Robert S ^a,b,d  

^a ST PAUL S HOSPITAL   (Canada)

^b Dept of Hlth Care and Epidemiol ^*  (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

AIDS; Antiretroviral therapy; British Columbia; HIV; Injection drug use; Life expectancy

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CANADA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LIFE EXPECTANCY; MALE; MODEL; MORTALITY; PREVALENCE; PRIORITY JOURNAL;

EID: 0033917372     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00021     Document Type: Article

References (29)

1. 1. Schechter MT, Hogg RS, Aylward B, Craib KJ, Le TN, Montaner JS. Higher socioeconomic status is associated with slower progression of HIV infection independent of access to health care. J Clin Epidemiol 1994, 47:59-67.
2. 2. Hu DJ, Fleming PL, Mays MA, Ward JW. The expanding regional diversity of the acquired immunodeficiency syndrome epidemic in the United States. Arch Intern Med 1994, 154:654-659.
3. 3. Hogg RS, Heath KV, Strathdee SA, Montaner JS, O'Shaughnessy MV, Schechter MT. HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials. AIDS 1996, 10:889-894.
4. 4. Burr KF, Costanzo GA, Hayer MV, MacNab YC, McKee B. Mortality and health status in Vancouver an analysis by neighbourhood areas. Victoria: BC Division of Vital Statistics; 1995.
5. 5. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997, 11:F59-65.
6. 6. Patrick DM, Strathdee SA, Archibald CP, et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS 1997, 8:437-445.
7. 7. Statistics Canada. 1996 Population Census of Canada.
8. 8. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280:547-549.
9. 9. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study [In Process Citation]. J Acquired Immune Defic Syndr 1999, 21 (Suppl. 1):S34-41.
10. 10. Phair JP. Determinants of the natural history of human immunodeficiency virus type 1 infection. J Infect Dis 1999, 179 (Suppl. 2):S384-386.
11. 11. Feinstein JS. The relationship between socioeconomic status and health: a review of the literature. Milbank Quarterly 1993, 71:279-322.
12. 12. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998, 12:279-284.
13. 13. Wood E, Low-Beer S, Bartholomew K, et al. Modern antiretroviral therapy improves life expectancy of gay and bisexual males in Vancouver's West End [In Process Citation]. Can J Public Health 1999, in press.
14. 14. The Futures Group International. DemProj Version 4. Spectrum Policy Project. 1997.
15. 15. Low-Beer S, Bartholomew K, Chan K, et al. A demographic and health profile of HIV-positive gay and bisexual men in the West End of Vancouver. Can J Infect Dis 1999, 10 (Suppl. B):62B.
16. 16. Stover J, Way P. Projecting the impact of AIDS on mortality. AIDS 1998, 12 (Suppl. 1):S29-S39.
17. 17. Health Canada. Consortium to characterize injection drug users in Canada (Montreal, Toronto, and Vancouver); 1998:
18. 18. Wood E, Yip B, Schilder A, Montaner JS, O'Shaughnessy MV, Hogg RS. The impact of HIV care and support on the mobility of persons taking anti-HIV therapy. Can J Infect Dis 1999; 10 (Suppl. B):48B.
19. 19. Bacchetti P, Moss AR. Incubation period of AIDS in San Francisco. Nature 1989, 338:251-253.
20. 20. Chevret S, Costagliola D, Lefrere JJ, Valleron AJ. A new approach to estimating AIDS incubation times: results in homosexual infected men. J Epidemiol Commun Health 1992, 46:582-586.
21. 21. Veugelers PJ, Cornelisse PG, Craib KJ, et al. Models of survival in HIV infection and their use in the quantification of treatment benefits. Am J Epidemiol 1998, 148:487-496.
22. 22. United Nations Population Division. World Population Prospects, the 1996 Revision. 1996.
23. 23. US Agency for International Development. World Population Profile. 1998.
24. 24. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy [see Comments]. JAMA 1998, 279:450-454.
25. 25. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen [see Comments]. AIDS 1997, 11:1249-1254.
26. 26. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group [see Comments]. N Engl J Med 1997, 337:1485-1490.
27. 27. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antiretroviral therapy [In Process Citation]. AIDS 1999, 13:963-969.
28. 28. Keiser P, Kvanli MB, Turner D, et al. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. J Acquired Immune Defic Syndr Hum Retrovirol 1999, 20:28-33.
29. 29. Palepu A, Strathdee S, Hogg, R, et al. The social determinants of emergency department and hospital use by injection drug users in Canada. Urban Health 1999, 76:409-418.